메뉴 건너뛰기




Volumn 85, Issue 2, 2009, Pages 111-115

Epidemiology and costs associated with genital warts in Canada

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; IMIQUIMOD; PODOPHYLLOTOXIN; SALICYLIC ACID;

EID: 65649086009     PISSN: 13684973     EISSN: 14723263     Source Type: Journal    
DOI: 10.1136/sti.2008.030999     Document Type: Article
Times cited : (67)

References (29)
  • 1
    • 0032840918 scopus 로고    scopus 로고
    • Human papillomavirus is a necessary cause of invasive cancer worldwide
    • Walboomers J. M. Jacobs M. V. Manos M. M. et al. Human papillomavirus is a necessary cause of invasive cancer worldwide. J Pathol 1999; 189: 12-19.
    • (1999) J Pathol , vol.189 , pp. 12-19
    • Walboomers, J.M.1    Jacobs, M.V.2    Manos, M.M.3
  • 2
    • 1542358952 scopus 로고    scopus 로고
    • Human papillomavirus vaccines and prevention of cervical cancer
    • Jansen K. U. Shaw A. R. Human papillomavirus vaccines and prevention of cervical cancer. Ann Rev Med 2004; 55: 319-31.
    • (2004) Ann Rev Med , vol.55 , pp. 319-331
    • Jansen, K.U.1    Shaw, A.R.2
  • 3
    • 0036221471 scopus 로고    scopus 로고
    • The causal relation between human papillomavirus and cervical cancer
    • Bosch F. X. Lorincz A. Muñoz N. et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244-65.
    • (2002) J Clin Pathol , vol.55 , pp. 244-265
    • Bosch, F.X.1    Lorincz, A.2    Muntild3    oz, N.4
  • 4
    • 0023815225 scopus 로고
    • Epidemiology of Genital human papillomavirus infection
    • Koutsky L. A. Galloway D. A. Holmes K. K. Epidemiology of genital human papillomavirus infection. Epidemiol Rev 1988; 10: 122-63.
    • (1988) Epidemiol Rev , vol.10 , pp. 122-63
    • Koutsky, L.A.1    Galloway, D.A.2    Holmes, K.K.3
  • 5
    • 54049087444 scopus 로고    scopus 로고
    • Merck Frosst Canada Ltd. Gardasil™ (Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine) 26 June (accessed Nov. 2008)
    • Merck Frosst Canada Ltd. Gardasil™ (Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine) product monograph, 26 June 2007. http://www.merckfrosst.ca/mfcl/en/corporate/products/gardasil.html (accessed Nov. 2008).
    • (2007) product monograph
  • 6
    • 65649106752 scopus 로고    scopus 로고
    • GlaxoSmithKline. Cervarix™ (Human papillomavirus (types 16, 18) product monograph, September (accessed Nov. 2008)
    • GlaxoSmithKline. Cervarix™ (Human papillomavirus (types 16, 18) recombinant adjuvanted, adsorbed vaccine) product monograph, September 2007. http://www.gsk.com (accessed Nov. 2008).
    • (2007) recombinant adjuvanted, adsorbed vaccine)
  • 7
    • 0037242467 scopus 로고    scopus 로고
    • Cost effectiveness of a potential vaccine for human papillomavirus
    • Sanders G. D. Taira A. V. Cost effectiveness of a potential vaccine for Human papillomavirus. Emerg Infect Dis 2003; 9: 37-48.
    • (2003) Emerg Infect Dis , vol.9 , pp. 37-48
    • Sers, G.D.1    Taira, A.V.2
  • 8
    • 0042661252 scopus 로고    scopus 로고
    • Potential health and economic impact of adding human papillomavirus vaccine to screening programs
    • Kulasingam S. L. Myers E. R. Potential health and economic impact of adding human papillomavirus vaccine to screening programs. JAMA 2003; 290: 781-9.
    • (2003) JAMA , vol.290 , pp. 781-789
    • Kulasingam, S.L.1    Myers, E.R.2
  • 9
    • 2342613014 scopus 로고    scopus 로고
    • Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine
    • Goldie S. J. Kohli M. Grima D. et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004; 96: 604-15.
    • (2004) J Natl Cancer Inst , vol.96 , pp. 604-615
    • Goldie, S.J.1    Kohli, M.2    Grima, D.3
  • 10
    • 34250827802 scopus 로고    scopus 로고
    • The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada
    • Brisson M. Van de Velde N. De Wals P. et al. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 2007; 25: 5399-408.
    • (2007) Vaccine , vol.25 , pp. 5399-5408
    • Brisson, M.1    Van De Velde, N.2    De Wals, P.3
  • 11
    • 34548301812 scopus 로고    scopus 로고
    • A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program
    • Kulasingam S. Connelly L. Conway E. et al. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sexual Health 2007; 4: 165-75.
    • (2007) Sexual Health , vol.4 , pp. 165-175
    • Kulasingam, S.1    Connelly, L.2    Conway, E.3
  • 12
    • 7644236858 scopus 로고    scopus 로고
    • Evaluating human papillomavirus vaccination programs
    • Taira A. V. Neukermans C. P. Sanders G. D. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004; 10: 1915-23.
    • (2004) Emerg Infect Dis , vol.10 , pp. 1915-1923
    • Taira, A.V.1    Neukermans, C.P.2    Sers, G.D.3
  • 13
    • 33846102585 scopus 로고    scopus 로고
    • Model for assessing human papillomavirus vaccination strategies
    • Elbasha E. H. Dasbach E. J. Insinga R. P. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007; 13: 28-41.
    • (2007) Emerg Infect Dis , vol.13 , pp. 28-41
    • Elbasha, E.H.1    Dasbach, E.J.2    Insinga, R.P.3
  • 14
    • 36849068973 scopus 로고    scopus 로고
    • Cost-effectiveness of quadrivalent human papillomavirus
    • (HPV) in Mexico: A transmission dynamic model-based evaluation
    • Insinga R. P. Dasbach E. J. Elbasha E. H. et al. Cost-effectiveness of quadrivalent human papillomavirus (HPV) in Mexico: a transmission dynamic model-based evaluation. Vaccine 2007; 26: 128-39.
    • (2007) Vaccine , vol.26 , pp. 128-139
    • Insinga, R.P.1    Dasbach, E.J.2    Elbasha, E.H.3
  • 15
    • 35648981545 scopus 로고    scopus 로고
    • The value of including boys in an HPV vaccination programme: A cost-effectiveness analysis in a low-resource setting
    • Kim J. J. Andres-Beck B. Goldie S. J. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer 2007; 97: 1322-8.
    • (2007) Br J Cancer , vol.97 , pp. 1322-1328
    • Kim, J.J.1    Andres-Beck, B.2    Goldie, S.J.3
  • 16
    • 65649152222 scopus 로고
    • Twenty year trends
    • Kliewer E. V. Demers A. A. Elliott L. et al. Twenty year trends (1985-2004) in the incidence and prevalence of anogenital warts in Manitoba. Winnipeg: Cancercare Manitoba, 2008: 45.
    • (1985) CancerCare Manitoba , pp. 45
    • Kliewer, E.V.1    Demers, A.A.2    Elliott, L.3
  • 18
    • 65649096768 scopus 로고    scopus 로고
    • Ministry of Health Services. Medical Services Plan. Information Resource Management Branch, Knowledge Management and Technology Division. (accessed Nov
    • Ministry of Health Services. Medical Services Plan. Information Resource Management Branch, Knowledge Management and Technology Division. Ministry of Health Services.http://www.gov.bc.ca/health/ (accessed Nov. 2008).
    • (2008) Ministry of health services
  • 19
    • 0003494060 scopus 로고    scopus 로고
    • Inventory of studies on the accuracy of Canadian health administrative databases
    • (publication no 96-03-TR)
    • Williams J. I. Young W. Inventory of studies on the accuracy of Canadian health administrative databases (publication no 96-03-TR). Toronto: Institute for Clinical Evaluative Sciences, 1996.
    • (1996) Toronto: Institute for Clinical Evaluative Sciences
    • Williams, J.I.1    Young, W.2
  • 20
    • 65649107517 scopus 로고    scopus 로고
    • Health Protection Agency (UK). Human papillomavirus (HPV)-cervical cancer and genital warts. (accessed March
    • Health Protection Agency (UK). Human papillomavirus (HPV) -cervical cancer and genital warts. Genitourinary surveillance data, http://www.hpa.org. uk/infections/topics-az/hiv-and-sti/Stats/STIs/warts/statistics.htm (accessed 5 March 2008).
    • (2008) Genitourinary surveillance data , vol.5
  • 22
    • 67049140987 scopus 로고    scopus 로고
    • Genital warts and associated health care use in general practice in Australia
    • 3-9 November
    • Conway E. L. Stein A. N. Britt H. et al. Genital warts and associated health care use in general practice in Australia. 24th International Papillomavirus Conference. 3-9 November 2007, Beijing, China [abstract]
    • (2007) 24th International Papillomavirus Conference
    • Conway, E.L.1    Stein, A.N.2    Britt, H.3
  • 23
    • 0038806720 scopus 로고    scopus 로고
    • The health and economic burden of Genital warts in a set of private health plans in the United States
    • Insinga R. P. Dasbach E. J. Myers E. R. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 2003; 36: 1397-403.
    • (2003) Clin Infect Dis , vol.36 , pp. 1397-1403
    • Insinga, R.P.1    Dasbach, E.J.2    Myers, E.R.3
  • 24
    • 65649092423 scopus 로고    scopus 로고
    • Patterns of treatment and resource utilization in the management of genital warts in Australian sexual health clinics
    • 3-9 November Beijing, China [abstract]
    • Morrow A. Chuah J. Conway E. L. et al. Patterns of treatment and resource utilization in the management of genital warts in Australian sexual health clinics. 24th International Papillomavirus Conference. 3-9 November 2007, Beijing, China [abstract]
    • (2007) 24th International Papillomavirus Conference
    • Morrow, A.1    Chuah, J.2    Conway, E.L.3
  • 25
    • 2942542546 scopus 로고    scopus 로고
    • The management of sexually transmitted infections by Australian practitioners
    • Johnston V. J. Britt H. Pan Y. et al. The management of sexually transmitted infections by Australian practitioners. Sex Transm Infect 2004; 80: 212-15.
    • (2004) Sex Transm Infect , vol.80 , pp. 212-215
    • Johnston, V.J.1    Britt, H.2    Pan, Y.3
  • 26
    • 33747892746 scopus 로고    scopus 로고
    • Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease
    • Lacey C. J. Lowndes C. M. Shah K. V. Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006; 24 (Suppl 3): 535-41.
    • (2006) Vaccine , vol.24 , Issue.3 SUPPL. , pp. 535-541
    • Lacey, C.J.1    Lowndes, C.M.2    Shah, K.V.3
  • 27
    • 65649138634 scopus 로고    scopus 로고
    • BC Cancer Agency
    • (accessed 13 May 2008)
    • BC Cancer Agency. Cervical cancer screening programme, 2006. http://www.bccancer.bc.ca/PPI/screening/cervical (accessed 13 May 2008).
    • (2006) Cervical cancer screening programme
  • 28
    • 41149115001 scopus 로고    scopus 로고
    • The validity of generic and condition-specific preference-based instruments: The ability to discriminate asthma control status
    • McTaggart-Cowan H. M. Marra C. A. Yang Y. et al. The validity of generic and condition-specific preference-based instruments: the ability to discriminate asthma control status. Qual Life Res 2008; 17: 453-62.
    • (2008) Qual Life Res , vol.17 , pp. 453-462
    • McTaggart-Cowan, H.M.1    Marra, C.A.2    Yang, Y.3
  • 29
    • 65649098240 scopus 로고    scopus 로고
    • Improving osteoarthritis detection in the community: Pharmacist identification of new, diagnostically confirmed osteoarthritis
    • Marra C. A. Cibere J. Tsuyuki R. T. et al. Improving osteoarthritis detection in the community: pharmacist identification of new, diagnostically confirmed osteoarthritis. Arthritis Rheum 2007; 15: 1238-44.
    • (2007) Arthritis Rheum , vol.15 , pp. 1238-1244
    • Marra, C.A.1    Cibere, J.2    Tsuyuki, R.T.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.